<DOC>
	<DOC>NCT01447485</DOC>
	<brief_summary>This study will assess the pharmacokinetics and safety following single dose of valsartan in Japanese pediatric patients with hypertension, chronic kidney disease, or nephrotic syndrome.</brief_summary>
	<brief_title>Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Japanese pediatric patients with hypertension, chronic kidney disease, or nephrotic syndrome GFR &lt; 30 mL/min/1.73 m2 Inability to safely tolerate the temporary discontinuation of concomitant antihypertensive medications (expect amlodipine or atenolol) from 24 hours prior to study drug administration to study completion. Inability to safely tolerate the temporary discontinuation of any drug known or suspected to effect hepatic or renal clearance capacity from 24 hours prior to study drug administration to study completion (this includes drugs that are known to cause induction or inhibition of hepatic enzymes). Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hypertension, chronic kidney disease</keyword>
	<keyword>nephrotic syndrome</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>